A carregar...
Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
Aims and methods: The aim of this monocentric retrospective observational study was to evaluate the 18-month safety and effectiveness of GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) 1.5 mg/once weekly as an add-on to metformin (MET) or MET plus conventional insulin secretagogues in a study coh...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7957905/ https://ncbi.nlm.nih.gov/pubmed/33801192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10050985 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|